China Journal of Leprosy and Skin Diseases ›› 2023, Vol. 39 ›› Issue (2): 73-76.doi: 10.12144/zgmfskin202302073

• Original Articles • Previous Articles     Next Articles

Assessment of leprosy registered active cases management measures in Shandong Province during 2011-2020

CHU Tongsheng, LIU Dianchang, HUAI Pengcheng, LIU Jian, ZHANG Furen   

  1. Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2023-02-15 Published:2022-12-27

Abstract: Objective: To assess the efficiency of registered reactive case management measures, the proporeion diagnosis and treatment of leprosy reaction, neuritis and adverse drug reactions, as well as the occurrence of new G2D among patients receiving MDT were analyzed. Methods: Traditional case management measures adopted include drug resistance monitoring, medical file electronization, supervision and technical guidance and personnel training. Specific measures of our province concise of follow-up at provincial level, provincial confirmation and management of leprosy reaction, neuritis and adverse drug reactions, precise prophylaxis of dapsone (DDS) hypersensitivity syndrome (DHS). The effectiveness of case management measures was evaluated by the detection and treatment proporeion of leprosy reaction, neuritis and adverse drug reaction and occurrence of new visible deformities during multi-drug therapy (MDT). Results: From 2011 to 2020, there were 328 registered active cases in Shandong Province, including 20 cases who were lost to follow up, 26 cases of death before cured, 2 emigrations, and 224 cases of recovery. By the end of 2020, there were still 56 active cases. All of the 312 episodes of leprosy reactions, 106 episodes of neuritis and 8 adverse drug reaction cases were diagnosed and treated during 2011-2020, the diagnosis and treatment rate reaching 100%. A total of 41 cases of newly diagnosed and severe active cases were admitted, including 34 episodes of neuritis and 41 episodes of leprosy reaction. The incidence of new deformity during MDT was 1.3%, much lower than the control target of no more than 10% in the national plan. Zhang Furen from Shandong Provincial Institute of Dermatology and Venerology identified HLA-B*13:01 as the risk site for DHS. All of those with positive HLA-B*13:01 screening results before MDT succeeded in escaping DHS by avoiding taking DDS. Conclusion: Through the unified management of current cases, diagnosis and treatment of leprosy reaction, neuritis and adverse drug reactions, and precise prevention of DDS hypersensitivity syndrome, the incidence of disability and death of current cases have been greatly reduced.

Key words: leprosy, leprosy registered active cases, DDS hypersensitivity syndrome